Academy Capital Management Sells 159 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Academy Capital Management reduced its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.5% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 34,013 shares of the company’s stock after selling 159 shares during the period. IDEXX Laboratories accounts for approximately 2.3% of Academy Capital Management’s holdings, making the stock its 11th largest holding. Academy Capital Management’s holdings in IDEXX Laboratories were worth $14,062,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Crew Capital Management Ltd. lifted its stake in IDEXX Laboratories by 24.0% in the fourth quarter. Crew Capital Management Ltd. now owns 2,569 shares of the company’s stock valued at $1,062,000 after buying an additional 498 shares during the period. Victory Capital Management Inc. increased its stake in shares of IDEXX Laboratories by 21.4% in the 4th quarter. Victory Capital Management Inc. now owns 173,131 shares of the company’s stock valued at $71,579,000 after acquiring an additional 30,503 shares during the last quarter. Commerzbank Aktiengesellschaft FI raised its position in shares of IDEXX Laboratories by 39.9% in the 4th quarter. Commerzbank Aktiengesellschaft FI now owns 918 shares of the company’s stock valued at $379,000 after acquiring an additional 262 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in IDEXX Laboratories by 3.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 531,692 shares of the company’s stock worth $219,823,000 after acquiring an additional 16,213 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC grew its holdings in IDEXX Laboratories by 9.8% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 2,436 shares of the company’s stock valued at $1,007,000 after purchasing an additional 218 shares during the period. 87.84% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on IDXX. Bank of America increased their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a report on Tuesday, February 4th. Morgan Stanley dropped their price objective on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 29th. StockNews.com upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Thursday, February 27th. Leerink Partners began coverage on IDEXX Laboratories in a report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price target for the company. Finally, Barclays lifted their price objective on IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $533.75.

Insider Transactions at IDEXX Laboratories

In other news, EVP George Fennell sold 9,986 shares of the firm’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the transaction, the executive vice president now owns 8,176 shares in the company, valued at $3,781,645.28. This trade represents a 54.98 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the sale, the director now directly owns 3,061 shares in the company, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 2.11% of the company’s stock.

IDEXX Laboratories Stock Up 1.0 %

Shares of IDEXX Laboratories stock opened at $441.61 on Wednesday. The firm has a market cap of $35.92 billion, a PE ratio of 41.39, a P/E/G ratio of 3.41 and a beta of 1.37. The business’s 50 day simple moving average is $436.35 and its 200 day simple moving average is $450.43. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. IDEXX Laboratories, Inc. has a 52-week low of $398.50 and a 52-week high of $574.94.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.